Resistant Starch Prebiotic Effects in Chronic Kidney Disease (ReSPECKD) study - Year two
Chronic Kidney Disease (CKD) is associated with a reduced quality of life and an increased risk of kidney failure, cardiovascular events, and all-cause mortality. The goal of this project is to investigate whether the consumption of resistant potato starch (RPS) in addition to current standard care for CKD will reduce uremic toxins and symptoms by altering gut microbiota in patients with CKD. Strategies to reduce the production of these toxins by the gut microbiome in patients with CKD are highly desirable because they may lead to reduced symptoms and delay the onset of dialysis. A clinical trial will be conducted at the partner's site, the Chronic Disease Innovation Centre (CDIC), to investigate the impact of RSP consumption on gut microbiota and whether these changes impact the concentrations of uremic toxins and uremic symptoms in patients with CKD. Delaying the onset of dialysis in a patient by 6 months has the potential to save upwards of $30,000 in healthcare expenditures. CDIC works with the Manitoba Renal Program which oversees the care of patients with CKD in Manitoba. The Elevate Fellow will support the start up and completion of the clinical trial at CDIC.